Leading figures from the artificial intelligence sector have united to urge US lawmakers to implement mandatory screening protocols for synthetic DNA and RNA purchases, aiming to prevent the development of AI-assisted biological weapons. In a recently circulated open letter directed at Congress, executives from Anthropic, OpenAI, Microsoft, Meta, and Google DeepMind joined representatives from prominent biotechnology firms to address a rapidly expanding biosecurity vulnerability. The correspondence, organized by the Foundation for American Innovation and the Institute for Progress, warns that generative AI models are significantly lowering the technical barriers required to engineer harmful pathogens. While synthetic genetic sequencing and laboratory assembly are already accessible to the public, AI capabilities are accelerating the design of dangerous biological sequences. This convergence threatens to democratize the creation of pathogens, chemical weapons, and engineered outbreaks that previously demanded highly specialized expertise and restricted laboratory infrastructure. Signatories include Anthropic CEO Dario Amodei, OpenAI CEO Sam Altman, Microsoft co-founder Mustafa Suleyman, Meta AI chief Alexandr Wang, and Google DeepMind founder Demis Hassabis. The initiative also garnered support from leading scientists, national security experts, and industry leaders from Twist Bioscience and Ansa Biotechnologies, both major suppliers of synthetic genetic material. Although many DNA and RNA providers currently implement voluntary screening processes to filter high-risk orders, the letter argues that these measures are insufficient against evolving AI capabilities. The authors are calling for legally binding requirements that mandate rigorous sequence screening for all commercial genetic material transactions. Additionally, the proposal demands comprehensive digital record-keeping to track purchases and identify threats that bypass initial filters. Officials emphasize that maintaining detailed transaction logs is critical for traceability and rapid response should a compromised sequence enter the supply chain. The briefing acknowledges the unprecedented consensus among technology executives, biotechnology manufacturers, and policy researchers who frequently operate with competing interests. The coalition stresses that regulatory frameworks must adapt to the accelerating pace of biological and computational innovation. By establishing mandatory verification standards and tracking mechanisms, policymakers could effectively close the current regulatory gap and mitigate the risk of engineered pandemics or state and non-state actor misuse. Industry stakeholders are requesting swift legislative action, framing the proposed safeguards as an immediate priority. The collective appeal underscores a critical shift in the technology landscape, where computational advancement directly intersects with global health security. Lawmakers are now facing pressure to translate this rare cross-sector alignment into enforceable biosecurity regulations before the window for preventative policy closes.